Long-term management of patients with metastatic renal cell carcinoma on targeted agents

References

• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind Phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J. Clin. Oncol.25(Suppl. 18) (2007) (Abstract 3).
   PubMedGoogle Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26(33), 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol.28(6), 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, Van Poppel H, De Prijck L, Sylvester R. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345(23), 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20(1), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol.27(34), 5794–5799 (2009).
   PubMed Web of Science ®Google Scholar
• Van Der Veldt AA, Meijerink MR, Van Den Eertwegh AJ et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res.14(8), 2431–2436 (2008).
   PubMed Web of Science ®Google Scholar
• Cowey CL, Amin C, Pruthi RS et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol.28(9), 1502–1507 (2010).
   PubMed Web of Science ®Google Scholar
• Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(25), 4076–4081 (2009).
   PubMed Web of Science ®Google Scholar
• Shuch B, Riggs SB, Larochelle JC et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int.102(6), 692–696 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol.181(2), 518–523 (2009).
   PubMed Web of Science ®Google Scholar
• Margulis V, Matin SF, Tannir N et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol.180(1), 94–98 (2008).
   PubMed Web of Science ®Google Scholar
• Thompson RH, Boorjian SA, Lohse CM et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J. Urol.179(2), 468–471 (2008).
   PubMed Web of Science ®Google Scholar
• Kavolius JP, Mastorakos DP, Pavlovich C et al. Resection of metastatic renal cell carcinoma. J. Clin. Oncol.16(6), 2261–2266 (1998).
   PubMed Web of Science ®Google Scholar
• Friedel G, Hurtgen M, Penzenstadler M, Kyriss T, Toomes H. Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res.19(2C), 1593–1596 (1999).
   Web of Science ®Google Scholar
• Golimbu M, Joshi P, Sperber A et al. Renal cell carcinoma: survival and prognostic factors. Urology27(4), 291–301 (1986).
   PubMed Web of Science ®Google Scholar
• Kierney PC, Van Heerden JA, Segura JW, Weaver AL. Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann. Surg. Oncol.1(4), 345–352 (1994).
   PubMed Web of Science ®Google Scholar
• Van Der Poel HG, Roukema JA, Horenblas S, Van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur. Urol.35(3), 197–203 (1999).
   PubMed Web of Science ®Google Scholar
• Daliani DD, Tannir NM, Papandreou CN et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int.104(4), 456–460 (2009).
   PubMed Web of Science ®Google Scholar
• Albiges L, Oudard S, Negrier S et al. Complete remission with TKI in renal cell carcinomas: experience in 65 patients of the French Kidney Cancer Group. J. Clin. Oncol.28(Suppl. 15) (2010) (Abstract 4600).
   Google Scholar
• Johannsen M, Staehler M, Ohlmann CH et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann. Oncol. DOI: 10.1093/annonc/mdq437 (2010) (Epub ahead of print).
   Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol.6(8), 465–477 (2009).
   PubMed Web of Science ®Google Scholar
• Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr. Opin. Support. Palliat. Care3(3), 170–179 (2009).
   PubMedGoogle Scholar
• Lipworth AD, Robert C, Zhu AX. Hand–foot syndrome (hand–foot skin reaction, palmar–plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology77(5), 257–271 (2009).
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Poland B et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol.66(2), 357–371 (2010).
   PubMed Web of Science ®Google Scholar
• Ilias-Khan NA, Khakoo AY, Tannir NM. A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib. J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 4601).
   Google Scholar
• Rini BI, Cohen DP, Lu D et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Presented at: The American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4–8 June 2010.
   Google Scholar
• Atkinson BJ, Tannir NM, Jonasch E. Schedule modifications and treatment outcomes for sunitinib-related adverse events. J. Clin. Oncol.28(Suppl.) (2010) (Abstract e15115).
   Google Scholar
• Di Lorenzo G, Autorino R, Bruni G et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann. Oncol.20(9), 1535–1542 (2009).
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet370(9604), 2011–2019 (2007).
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer112(11), 2500–2508 (2008).
   PubMed Web of Science ®Google Scholar
• Constantiner M, Sehgal AR, Humbert L et al. A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. Am. J. Kidney Dis.45(5), 833–841 (2005).
   PubMed Web of Science ®Google Scholar
• Atkinson BJ, Wilhelm KL, Khakoo AY, Tannir NM, Jonasch E. A retrospective evaluation of antiangiogenic therapy-induced hypertension in metastatic renal cell carcinoma. J. Clin. Oncol.28(Suppl.) (2010) (Abstract e15047).
   Google Scholar
• Dubauskas Z, Kunishige J, Prieto VG et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin. Genitourin. Cancer7(1), 20–23 (2009).
   PubMed Web of Science ®Google Scholar
• Arnault JP, Wechsler J, Escudier B et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol.27(23), e59–e61 (2009).
   PubMed Web of Science ®Google Scholar
• Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol.10(10), 967–974 (2009).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol.28(13), 2280–2285 (2010).
   PubMed Web of Science ®Google Scholar
• Rini B I, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst.99(1), 81–83 (2007).
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol.19(2), 265–268 (2008).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann. Oncol.19(8), 1387–1392 (2008).
   PubMed Web of Science ®Google Scholar